Genus Capital Management Inc. Invests $742,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Genus Capital Management Inc. acquired a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,600 shares of the medical equipment provider's stock, valued at approximately $742,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Janus Henderson Group PLC grew its stake in shares of Lantheus by 72.7% in the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its stake in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock worth $475,590,000 after acquiring an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after acquiring an additional 435,445 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock worth $120,510,000 after acquiring an additional 30,891 shares during the period. Finally, Silvercrest Asset Management Group LLC grew its stake in shares of Lantheus by 39.1% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock worth $87,124,000 after acquiring an additional 273,838 shares during the period. 99.06% of the stock is currently owned by institutional investors.

Lantheus Price Performance

NASDAQ:LNTH traded down $2.52 during trading hours on Friday, hitting $81.31. 816,768 shares of the stock traded hands, compared to its average volume of 981,028. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49. Lantheus Holdings, Inc. has a 1 year low of $73.11 and a 1 year high of $126.89. The company has a market cap of $5.63 billion, a price-to-earnings ratio of 23.10 and a beta of 0.12. The stock has a 50 day moving average price of $80.26 and a 200 day moving average price of $89.94.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same period in the prior year, the firm earned $1.69 EPS. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. Sell-side analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the transaction, the director owned 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LNTH has been the topic of a number of research reports. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Truist Financial dropped their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Finally, B. Riley dropped their price objective on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a report on Monday, June 23rd. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $131.20.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.